Summit Therapeutics Inc.(SMMT)
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest News & Analysis
Summit Therapeutics (SMMT) Strategic Update: Ivonescimab Deal, Financial Health, and Market Position
Summit Therapeutics advances with a pivotal Ivonescimab licensing deal with AstraZeneca, navigating clinical efficacy, legal challenges, and financial stability.
Summit Therapeutics (SMMT) Update: Securities Fraud Allegations, Ivonescimab Trial Setbacks, and Strategic Outlook
Summit Therapeutics faces securities fraud probes after ivonescimab missed key trial endpoints, causing a 30.5% stock drop. Analysis of financials, legal risks, and partnership prospects.
Summit Therapeutics Inc. (SMMT) Clinical, Legal Risks Cloud $15B AstraZeneca Deal
Summit Therapeutics faces critical legal scrutiny and clinical challenges as its $15B AstraZeneca deal hinges on Ivonescimab's mixed trial data and financial health.
Summit Therapeutics Inc. $15B AstraZeneca Deal and Financial Performance Analysis - SMMT Insights
Summit Therapeutics (SMMT) surges on a $15B AstraZeneca licensing deal for ivonescimab amid litigation and clinical trial scrutiny, reshaping NSCLC treatment prospects.
Summit Therapeutics (SMMT) Analysis: Ivonescimab Deal Risks, Financials & AstraZeneca Partnership
Explore Summit Therapeutics' ivonescimab clinical promise, $15B AstraZeneca deal risk amid securities fraud probes, and key financial insights for investors.
Summit Therapeutics Inc. $15B AstraZeneca Ivonescimab Deal: Clinical Promise Amid Legal and Regulatory Risks
Summit Therapeutics' potential $15B deal with AstraZeneca for ivonescimab highlights clinical promise in NSCLC but faces legal and regulatory hurdles impacting investor outlook.
Summit Therapeutics Inc. (SMMT) $15B AstraZeneca Deal Amid Clinical and Legal Challenges
Summit Therapeutics strikes a $15B licensing deal with AstraZeneca for ivonescimab, balancing promising clinical data against ongoing legal investigations.
Summit Therapeutics Inc. (SMMT) Market Analysis: Legal Challenges and Clinical Developments Impact
Summit Therapeutics faces legal scrutiny and mixed clinical results amid a strategic oncology partnership, impacting financials and investor sentiment.
Summit Therapeutics Inc. (SMMT) Market Update: Navigating Legal Challenges Amid Strategic Oncology Collaboration
Summit Therapeutics faces investor claims and legal scrutiny amid its promising collaboration with Revolution Medicines on RAS mutant tumor therapies.
Summit Therapeutics (SMMT): Clinical Setbacks and Legal Challenges
Summit Therapeutics (SMMT) faces scrutiny after mixed trial results and a Pomerantz LLP probe. Explore the stock's plunge, analyst downgrades, and financial implications.
Summit Therapeutics (SMMT): Legal Headwinds & Clinical Milestones Analysis
Summit Therapeutics navigates legal challenges and critical clinical milestones, with its stock reacting to recent legal scrutiny and pipeline updates.
Summit Therapeutics ([SMMT](/dashboard/companies/SMMT)): Clinical Milestones & Legal Headwinds
Explore Summit Therapeutics' dual narrative of clinical success with ridinilazole and ongoing legal probes. Analyze SMMT's financials, strategy, and future outlook.
Summit Therapeutics (SMMT): Navigating Legal Scrutiny and Clinical Milestones
Summit Therapeutics (SMMT) faces legal probes and market volatility while advancing key clinical programs, shaping its 2025 trajectory.
Summit Therapeutics (SMMT): Navigating Clinical Hurdles and Legal Scrutiny
Summit Therapeutics (SMMT) navigates dual challenges: mixed clinical trial results for ivonescimab and ongoing legal investigations, shaping its market trajectory.
Summit Therapeutics (SMMT): Clinical Trials, Analyst Ratings, and Outlook
Analysis of Summit Therapeutics (SMMT): Clinical trials, analyst ratings, market outlook, inducement grants, and macroeconomic factors impacting investment potential.
Summit Therapeutics (SMMT): Pipeline Progress & Strategic Analysis
Analysis of Summit Therapeutics (SMMT): Analyst optimism, pipeline progress, strategic collaborations, and market volatility. Key developments and financial insights.
Summit Therapeutics (SMMT): Leadership, Pfizer Deal, Ivonescimab
Analysis of Summit Therapeutics (SMMT): leadership changes, Pfizer collaboration, and ivonescimab's potential in NSCLC treatment.
SMMT: Summit Therapeutics' Ivonescimab & Pfizer Collaboration
Analysis of Summit Therapeutics' collaboration with Pfizer, focusing on ivonescimab's potential in NSCLC treatment and financial implications for investors.
Summit Therapeutics (SMMT): Q4 Loss, Pfizer Deal, and Ivonescimab's Promise
Summit Therapeutics faces Q4 loss but a Pfizer collaboration boosts ivonescimab's potential. This analysis covers financials, market landscape, and future prospects.
Summit Therapeutics: Q4 Results and Pfizer Collaboration – A Game Changer?
Summit Therapeutics balances Q4 results with a Pfizer collaboration, focusing on Ivonescimab's potential. Mid-2025 NSCLC data is crucial for its future.
Summit Therapeutics: Q4 Results, Pfizer Collaboration, Ivonescimab
Summit Therapeutics navigates market volatility with Q4 results, a Pfizer collaboration, and ivonescimab's potential. A comprehensive analysis of recent developments.
Summit Therapeutics: Ivonescimab's NSCLC Trial Results - A Game Changer?
A deep dive into Summit Therapeutics' Ivonescimab, its clinical trial results, financial outlook, and potential impact on the NSCLC treatment landscape.